Efficacy of Low‐Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double‐Blind Randomized Clinical Trial
Open Access
- 28 March 2025
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 14 (7) , e70837
Abstract
Background: Invasive fungal infections (IFIs), particularly Candida infections, are a significant cause of morbidity and mortality in patients with acute leukemia. While fluconazole is widely used for prophylaxis, the optimal dosing regimen remains uncertain. This study aimed to evaluate the efficacy of low‐dose fluconazole for primary prophylaxis against invasive Candida infections in patients with acute leukemia receiving intensive chemotherapy.Methods: A double‐blind, randomized clinical trial was conducted with patients diagnosed with acute leukemia. Patients were assigned to receive either low‐dose (150 mg/day) or standard high‐dose (400 mg/day) fluconazole for primary prophylaxis against invasive Candida infections during intensive chemotherapy. The primary outcomes were the efficacy of antifungal prophylaxis and the safety profile.Results: A total of 120 patients (60 per group) were enrolled. The overall incidence of Candida infections was similar between the groups (p = 0.615). Candida colonization was higher in the low‐dose fluconazole group during the first week, particularly with non‐albicans Candida at oral and subaxillary sites (p < 0.001). However, by the third week, both groups showed a significant decline in colonization, with the reduction in the oral cavity being statistically significant (p = 0.03). Aspergillosis occurred in 38.3% of patients, with no significant difference between groups (p > 0.99). Adverse events were similar in both groups (p > 0.05).Conclusion: Low‐dose fluconazole is an effective alternative to high‐dose regimens for preventing Candida infections in acute leukemia patients, with similar efficacy and safety. The rising threat of aspergillosis highlights the need for targeted prophylaxis. Further research is needed to refine strategies for high‐risk patients.Trial Registration: Iranian Registry of Clinical Trials (IRCT) number: IRCT20140818018842N37Keywords
This publication has 34 references indexed in Scilit:
- Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasisBMC Infectious Diseases, 2014
- A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignanciesClinical Microbiology and Infection, 2014
- Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001‐2007)Cancer, 2009
- Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxisPediatric Blood & Cancer, 2008
- Risk of resistance associated with fluconazole prophylaxis: Systematic reviewJournal of Infection, 2007
- A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in JapanBone Marrow Transplantation, 2004
- Fluconazole to prevent yeast infections in bone marrow transplantation patients:The American Journal of Medicine, 2002
- Antifungal Prophylaxis in Severely Neutropenic Patients: How Much Fluconazole is Necessary?Clinical Microbiology and Infection, 1995
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationNew England Journal of Medicine, 1992